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Transforming growth factor beta (TGF-β) is the most potent pro-ﬁbrogenic cytokine and its expression is
increased in almost all of ﬁbrotic diseases. Although signaling through Smad pathway is believed to play
a central role in TGF-β's ﬁbrogenesis, emerging evidence indicates that reactive oxygen species (ROS)
modulate TGF-β's signaling through different pathways including Smad pathway. TGF-β1 increases ROS
production and suppresses antioxidant enzymes, leading to a redox imbalance. ROS, in turn, induce/
activate TGF-β1 and mediate many of TGF-β's ﬁbrogenic effects, forming a vicious cycle (see graphic ﬂow
chart on the right). Here, we review the current knowledge on the feed-forward mechanisms between
TGF-β1 and ROS in the development of ﬁbrosis. Therapeutics targeting TGF-β-induced and ROS-de-
pendent cellular signaling represents a novel approach in the treatment of ﬁbrotic disorders.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565
2. TGF-β1 and ﬁbrosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
3. TGF-β induces redox imbalance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
3.1. TGF-β increases mitochondrial ROS production. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
3.2. TGF-β increases ROS production through inducing NADPH oxidases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567
3.3. Suppression of antioxidant system by TGF-β . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 568
4. Redox regulation of TGF-β1 activity and expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 568
5. ROS mediate TGF-β-induced ﬁbrotic responses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 569
5.1. TGF-β, ROS, and ﬁbroblast activation/myoﬁbroblast differentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 569
5.2. TGF-β, ROS, and epithelial apoptosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 569
5.3. ROS mediate TGF-induced epithelial–mesenchymal transition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570
5.4. TGF-β-mediated redox regulation of plasminogen activator inhibitor 1 gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 571
6. In summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 571
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 571
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5711. Introduction
Transforming growth factor beta (TGF-β), the most potent andB.V. This is an open access article u
gy and Critical Care, Depart-
Alabama at Birmingham, Bir-ubiquitous proﬁbrogenic cytokine, plays a central role in the de-
velopment of ﬁbrosis involving almost all organ systems [1–4].
Although TGF-β1 signaling through Smad pathway is believed to
be responsible for the induction of many of TGF-β's responsive
genes emerging evidence indicates that reactive oxygen (ROS)
mediate TGF-β's signaling through different pathways including
Smad pathway, mitogen activated protein kinase (MAPK) path-
ways, and Rho-GTPase pathway. TGF-β1 increases the productionnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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oxidases (NOXs), mainly Nox4, a non-phagocytic NOX expressed
by many different types of cells. TGF-β also suppresses antioxidant
system including the synthesis of glutathione (GSH), the most
abundant intracellular free thiol and an important antioxidant,
and several other antioxidant enzymes, leading to oxidative stress
or redox imbalance. Such a redox imbalance in turn induces/acti-
vates TGF-β1 and mediates TGF-β's ﬁbrogenic effects [5]. In this
review, we will focus on the mechanisms whereby TGF-β induces
Nox4 and causes redox imbalance as well as the mechanisms
whereby ROS activate/induce TGF-β and mediate TGF-β's ﬁbro-
genic effects. Suppression of TGF-β-induced ROS production may
break this vicious cycle and have therapeutic potential for the
treatment of ﬁbrotic disorders.2. TGF-β1 and ﬁbrosis
Fibrosis is characterized by increased deposition of extra-
cellular matrix (ECM) proteins in the interstitial, leading to stiff-
ness and loss of organ architecture and function. Fibrosis affects
almost all organ systems and accounts for 45% of disease-related
death. Many cytokines/chemokines/growth factors contribute to
the development of ﬁbrosis; however, TGF-β is considered to be
the most potent and ubiquitous proﬁbrogenic cytokine. TGF-β
mRNA and/or protein expression is increased in almost all ﬁbrotic
diseases involved in different organ systems and in experimental
ﬁbrosis models [6–18]. Overexpression of TGF-β induces [19–29]
whereas administration of TGF-β binding proteins, anti-TGF-β
antibody, or an inhibitor to TGF-β type I receptor ALK5 ameliorated
ﬁbrosis [24,30–33]. All these lines of evidence suggest that TGF-β
plays a pivotal role in the development of ﬁbrosis. Although it has
been well documented that TGF-β exits its proﬁbrogenic activity
through activating ﬁbroblasts, a recent study shows that epithe-
lium-speciﬁc deletion of TGF-β receptor type II protects mice from
bleomycin-induced lung ﬁbrosis, suggesting that TGF-β signaling
in epithelial cells is also important for its ﬁbrogenic effects [34].
TGF-β, existing in three isoforms, TGFβ1, TGFβ2, and TGFβ3, is
secreted by many different types of cells and involved in various
cell functions including cell proliferation, differentiation, apopto-
sis, adhesion, and migration. Although all three isoforms are ex-
pressed in ﬁbrotic tissues, the development of lung ﬁbrosis is
primarily attributed to TGFβ1 [35]. TGF-β1 signaling through Smad
pathway, the canonical pathway, has been well described. Active
TGF-β binds to type II receptor (TGFβR-II) on the cell membrane,
which activates type I receptor (TGFβR-I), leading to phosphor-
ylation of Smad2 and Smad3. Phosphorylated Smad2 and Smad3
then form a complex with common mediator Smad (Co-Smad),
Smad4, which translocates to the nucleus and regulates gene
transcription through binding to Smad binding elements present
in the promoter of the target genes [36]. There are 7 mammalian
type I receptors, termed ALK1-7 (activin receptor-like kinase 1-7)
and TGF-β1 signaling mainly through ALK-5 [37]. Inhibitory
Smads, Smad6 and Smad7, on the other hand, negatively regulate
TGF-β signaling by binding to type I receptor or by competing with
Smad2/3 for binding to Smad4 [38–40]. Numerous studies have
shown that TGF-β1 plays a central role in the development of ﬁ-
brosis in many tissues/organs under various pathological condi-
tions through ALK-5 and Smad2/3 pathway [41–47]. The counter-
regulatory role of Smad7 in the development of ﬁbrosis has also
been demonstrated in several cell types and in vivo [40,48,49].
Besides Smad pathways, studies have shown that TGF-β signaling
through other non-canonical pathways, including mitogen acti-
vated protein kinase (MAPK) pathways, phosphatidylinositol-3-
kinase (PI3K) pathway, and Rho-like GTPase pathways, are also
critical for eliciting TGF-β's proﬁbrogenic activity [25,38,50–61].TGF-β has been shown to activate MAPK pathways through TGF-β-
activated kinase 1 (TAK1), a MAPK kinase kinase, or through Ras
[38] in different types of cells [25,51–57]. Importantly, it has been
well documented that MAPK pathways are redox sensitivity, al-
though the redox sensitivity molecules in these pathways remain
to be identiﬁed. Rho-GTPases, a subfamily of small GTP-binding
proteins within the Ras superfamily, regulates actin cytoskeleton,
cell shape, adhesion, and migration. Rho-GTPase and its down-
stream effector ROCK have been shown to be involved in TGF-β-
induced myoﬁbroblast differentiation [61–67]. Interestingly, it has
been reported that ROS derived from mitochondria, NADPH oxi-
dases, or other sources activate RhoA [68–74] and that Nox4-de-
rived ROS mediate TGF-β1-induced kidney myoﬁbroblast differ-
entiation through activating RhoA/Rho kinase pathway [61].3. TGF-β induces redox imbalance
Redox imbalance or oxidative stress results from an increased
production of reactive oxygen or nitrogen species (ROS/RNS) and/
or reduced antioxidant capacity. ROS/RNS such as superoxide,
hydrogen peroxide (H2O2), and nitric oxide (NO) are formed as a
byproduct of the normal metabolism of oxygen and have im-
portant function in cell signaling and homeostasis. Overproduction
of ROS/RNS, however, contributes to the pathophysiology of many
diseases. Biological systems have developed superior antioxidant
mechanisms, enzymatic and non-enzymatic, to scavenge or re-
move ROS/RNS generated during normal metabolism or under
pathological conditions. The enzymatic system comprises mainly
the superoxide dismutases (SODs), catalase, glutathione perox-
idase (GPx), and peroxiredoxin; whereas non-enzymatic system
includes glutathione (GSH), ascorbic acid, β-carotene, and α-to-
copherol. TGF-β has been shown to increase ROS production and
suppress antioxidant system and thereby induce oxidative stress
or redox imbalance. Such a redox imbalance contributes im-
portantly to TGF-β's pathophysiologic effects including ﬁbrosis
[75].
3.1. TGF-β increases mitochondrial ROS production
Mitochondria are the major source of ROS in cells. TGF-β1 has
been shown to increase mitochondrial ROS production in different
types of cells, which mediate TGF-β-induced cell apoptosis [76–
80], senescence [81–83], epithelia–mesenchymal transition [84],
ﬁbrotic gene expression and myoﬁbroblast differentiation [85,86];
Ishikawa et al. reported that TGF-β increased ROS levels in the
cytoplasm and mitochondria in mouse mammary epithelial cells
(NMuMG) and decreased mitochondrial membrane potential [84].
Depletion of mitochondria (pseudo p0 cells), on the other hand,
abrogated TGF-β-induced increase in intracellular ROS [84] The
authors also showed that exogenously expressed mitochondrial
thioredoxin inhibited TGF-β-induced expression of ﬁbronectin and
HMGA2, a central mediator of epithelial–mesenchymal transition
(EMT), suggesting a novel mechanism involving mitochondria in
TGF-β-mediated gene expression associated with EMT [84]. Dif-
ferent mechanisms whereby TGF-β stimulates mitochondrial ROS
production have been proposed. Yoon et al showed that TGF-β
induced a prolonged mitochondrial ROS production through de-
creasing complex IV activity in Mv1Lu cells, a mink lung epithelial
cell line [81]. Using a speciﬁc inhibitor and siRNA to glycogen
synthase kinase 3 (GSK3), Byun et al. further showed that phos-
phorylation of GSK α and β subunits may underlie the inhibition of
complex IV activity and thereby mitochondrial ROS production by
TGF-β1 [82]. Jain et al reported, on the other hand, that TGF-β
increased ROS levels in both normal and ﬁbrotic human lung ﬁ-
broblasts by blocking complex III activity [85]. They further
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or genetically disrupting mitochondrial complex III activity atte-
nuated TGF-β-induced expression of proﬁbrotic genes, including
alpha smooth muscle actin (α-SMA) and connective tissue growth
factor (CTGF), but had no signiﬁcant effect on Smad phosphor-
ylation or nuclear translocation, suggesting that mitochondria
derived ROS mediate TGF-β's ﬁbrogenic activity independent of
Smad pathway [85]. TGF-β has also been shown to increase mi-
tochondria oxygen consumption and ROS production through ac-
tivating mammalian target of rapamycin (mTOR) pathway in
mouse podocytes [87].
3.2. TGF-β increases ROS production through inducing NADPH
oxidases
NAPDH oxidases (Noxs) are a group of heme-containing
transmembrane proteins and important ROS producers for both
phagocytic and non-phagocytic cells, although the biological
functions of ROS generated in non-phagocytic cells are unclear at
moment. Seven members have been identiﬁed in the Nox family:
Nox1, Nox2, Nox3, Nox4, Nox5, Dual oxidase1 (Duox1), and Dual
oxidase 2 (Duox2). TGF-β has been shown to induce the expres-
sion of several Nox enzymes including Nox 1, Nox2, and Nox4 in
different types of cells [60,80,88–101]. Of all Nox family members,
the induction and role of Nox4 in TGF-β's ﬁbrogenesis has been
studied most [60,90–101]. Different from other Nox isoforms, Nox
4 is constitutively active and is expressed by many types of non-
phagocytic cells including epithelial, endothelial, macrophage, and
ﬁbroblasts. Nox4 protein has been found to be associated with
different cell compartments including endoplasmic reticulum (ER)
[94,102–104], perinuclear space [105], nucleus [94,100,106], and
mitochondria [107–109]. A large body of literatures has shown
that TGF-β induces Nox4 expression in various types of cells
[80,91,93–101,110] and that Nox4-derived ROS mediate TGF-β's
ﬁbrogenic effects, including ﬁbroblast activation/myoﬁbroblast
differentiation [88,92,96,111–113], epithelial and endothelial cell
apoptosis [80,91,98,114], epithelia–mesenchymal transition [101],
and the expression of ﬁbrotic/proﬁbrotic genes [58,88,100,115]. An
increase in Nox4 expression has also been detected in ﬁbrotic
diseases including idiopathic pulmonary ﬁbrosis (IPF), which cor-
relates with increased expression of myoﬁbroblast marker, α-SMA,
further supporting the role of Nox4 in ﬁbrotic diseases [111,116–
118].
Several pathways have been shown to be involved in the in-
duction of Nox4 by TGF-β, including Smad pathway
[92,93,101,111,119,120], PI3K pathway [95,119], MAPK pathways
[112,114], and RhoA/ROCK pathway [61]. Hecker et al. showed that
TGF-β1 increased Nox4 expression with no effect on the expres-
sion of other Nox family members in human lung mesenchymal
cells (hFLMCs) [111]. Treatment of hFLMCs with an inhibitor to
TGF-β type I receptor (ALK-5) or transfection of cells with Smad3
siRNA almost completely blocked TGF-β-induced Nox4 expression
and H2O2 production. In contrast, treatment of cells with inhibitors
of to p38/ERK/JNK MAKP pathways had no signiﬁcant effect on
TGF-β-induced Nox4 expression [111], suggesting that Smad
pathway not MAPK pathway, mediates the induction of Nox4 by
TGF-β in lung mesenchymal cells. Using similar strategies, Yeh and
Bondi also showed that Smad3 pathways were involved in Nox4
induction by TGF-β in ﬁbroblasts [92,120]. TGF-β induction of
Nox4 in epithelial cells is also mediated through Smad pathway
[101]. Boudreau et al. reported that TGF-β induced Nox4 expres-
sion and increased ROS production in human breast epithelial cells
(MCF10A and MDA-MB-231); knockdown of Nox4 expression by
siRNA or shRNA techniques signiﬁcantly reduced TGF-β-induced
ROS production and ﬁbronectin mRNA expression [101]. Further-
more, they demonstrate that overexpression of constitutivelyactive Smad3 increased whereas treatment with dominant-nega-
tive Smad3 or Smad3 inhibitor, SIS3 suppressed TGF-β-induced
Nox4 expression [101]. However, conﬂicting results have been
reported regarding whether Nox4-derived ROS is involved in Smad
activation in TGF-β signaling process. Bondi et al. showed that
TGF-β induces Nox2 and Nox4 in kidney myoﬁbroblasts [92].
Treatment of ﬁbroblasts with Nox inhibitor diphenyleneiodonium
(DPI) had no signiﬁcant effect on TGF-β-induced Smad3 phos-
phorylation but reduced TGF-β-stimulated α-SMA and ﬁbronectin
expression. Moreover, they showed that inhibition of Smad3 with
inhibitor SIS3 reduced Nox4 expression and activity as well as
TGF-β-induced ﬁbrotic responses. These data further support the
notion that Smad3 functions upstream of Nox4 and also suggest
that Nox-derived ROS is not involved in Smad activation [92]. In
contrast with above ﬁnding, Cucoranu et al. reported that TGF-β1
induced Nox4 in cardiac ﬁbroblast; knockdown of Nox4 with
Nox4siRNA blocked TGF-β-induced ROS production, α-SMA ex-
pression, and Smad2/3 phosphorylation, suggesting that Nox4-
derived ROS mediate TGF-β1-induced Smad2/3 activation cardiac
ﬁbroblasts [96].
PI3K pathway has also been shown to be involved in the in-
duction of Nox4 by TGF-β [95,119], Michaeloudes et al. showed
that TGF-β induced Nox4 but suppressed the expression of man-
ganese-superoxide dismutase (Mn-SOD) and catalase, associated
with an increase in ROS production and IL-6 expression in human
airway smooth muscle cells [119]. Inhibition of Smad3 pathway by
dominant negative technique or inhibition of PI3K pathway with
LY294002 signiﬁcantly reduced TGF-β1-induced Nox4 mRNA ex-
pression in these cells, suggesting that both Smad3 and PI3K
pathways are involved in Nox4 induction by TGF-β in these cells
[119]. Ismail et al. showed that hypoxia induced TGF-β, insulin-like
growth factor binding protein-3 (IGFBP-3), and Nox4 and pro-
moted proliferation in human pulmonary artery smooth muscle
cells; anti-TGF-β antibody, on the other hand, attenuated hypoxia-
mediated induction of Nox4, IGFBP-3, and cell proliferation [95].
They also showed that inhibition of PI3K pathway, but not Smad
pathway, attenuated hypoxia-induced Nox4 and IGFBP-3 expres-
sion as well as cell proliferation [95]. Their results suggest that
TGF-β mediated hypoxia-induced Nox4 expression and cell pro-
liferation in human pulmonary artery smooth muscle cells through
activation of PI3K pathway [95]. Using a pharmaceutical inhibitor
and shRNA/siRNA techniques, Tobar et al. reported that JNK
pathway, but not Smad pathway, was involved in TGF-β-induced
Nox4 expression in human breast stromal cells [112]. Interestingly,
Caja et al. showed that TGF-β induced Nox4 in liver tumor cells
only when the cells were treated with ERK inhibitor PD98059,
suggesting that ERK pathway suppresses Nox4 expression in these
cells [114]. Taken together, these data suggest that TGF-β induces
Nox4 gene expression in different types of cells through different
signaling pathways.
Emerging evidence suggests that there is crosstalk between
mitochondria and NADPH oxidases: mitochondria-derived ROS
contribute to the increase in NOX expression in response to TGF-β
whereas NOX-generated ROS cause mitochondria dysfunction and
increase mitochondrial ROS production [121–124]. It is reported
that Nox4 expression is increased in mitochondria of aged mice;
suppression of Nox4 expression with Nox4 shRNA decreases mi-
tochondrial ROS level and improves mitochondrial function in
vascular smooth muscle cells from aged mice, supporting the no-
tion that a feed-forward relation between mitochondria and Nox4
in ROS production may underlie increased oxidative stress and
cardiac dysfunction during aging [125]. Crosstalk between mi-
tochondria and Nox enzyme has also been shown to mediate TGF-
β's proﬁbrogenic effect. Jain et al. showed that TGF-β induced the
expression of proﬁbrogenic proteins including α-SMA and CTGF
through increasing mitochondrial ROS whereas mitochondria
Fig. 1. TGF-β induces redox imbalance by increasing ROS production and sup-
pressing antioxidant defense. TGF-β1 increases ROS production by disrupting mi-
tochondrial function and inducing ROS-generating enzymes NADPH oxidases
(Noxs). TGF-β1 also suppresses the expression of the enzymes involved in the an-
tioxidant defense, including superoxide dismutase (SOD), catalase, glutaredoxin
(Grx), and glutamate cysteine ligase, which leads to a decrease in GSH
concentration.
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expression of proﬁbrotic genes but also the expression of Nox4
[85], suggesting a feed-forward interaction between mitochondria
and Nox4 in TGF-β-induced ROS production.
3.3. Suppression of antioxidant system by TGF-β
Besides stimulation of ROS production, TGF-β can also induce
redox imbalance by suppressing antioxidant system. Glutathione
(GSH) is the most abundant intracellular free thiol and has mul-
tiple functions, including detoxiﬁcation of electrophiles and
synthesis of endogenous compounds such DNA. The most im-
portant function of GSH, however, is antioxidant defense. GSH can
reduce hydrogen peroxide and lipid peroxides through GPx-cata-
lyzed reactions and is also involved in reduction of oxidized pro-
tein thiols (cysteine residues) through glutaredoxin (Grx) cata-
lyzed reactions. Importantly, GSH concentration decreases in var-
ious ﬁbrotic diseases including cystic ﬁbrosis [126,127], chronic
obstructive pulmonary disease (COPD) [128], acute respiratory
distress syndrome (ARDS) [129–133], IPF [134–140], sarcoidosis
[141], and chronic liver diseases [142–148]. GSH concentration is
also decreased in experimental ﬁbrosis models induced by differ-
ent stimuli [25,149–158]. Although the mechanism leading to GSH
depletion in ﬁbrotic diseases remains unclear, emerging evidence
suggests that increased TGF-β may contribute to this effect
[25,91,159–168]. De novo GSH synthesis is a two-step reaction
catalyzed by glutamate cysteine ligase (GCL) and GSH synthase
(GS). GCL is the rate limiting enzyme in de novo GSH synthesis and
is composed of two subunits, the catalytically active heavy subunit
(GCLC) and the modiﬁer light subunit (GCLM). It has been reported
that TGF-β suppresses the expression of GCLC genes and decreases
GSH concentration in different types of cells in vitro [91,159–
165,167,168]. In a previous study, we showed that administration
of AdTGF-β1223/225, an adenovirus expressing constitutively active
TGF-β1, suppressed the expression of both GCLC and GCLMmRNAs
and proteins, inhibited the GCL activity, and reduced GSH level in
mouse lung tissue [25]. This was associated with induction of ac-
tivating transcription factor 3 (ATF3), a transcriptional repressor
involved in the regulation of GCLC [25,167]. A decreased GCL gene
expression is also reported in ﬁbrotic diseases [140,169]. Together,
the data suggest that increased TGF-β expression may underlie the
depletion of GSH observed in ﬁbrotic diseases. As GSH is the most
abundant intracellular free thiol and the ratio of GSH and glu-
tathione disulﬁde (GSSG) determines cell redox status [170], a
decrease in GSH concentration will lead to increased oxidative
stress level or redox imbalance.
Superoxide, a highly reactive oxygen species, is generated un-
der both physiological and pathological conditions, which is con-
verted by superoxide dismutase (SOD) to hydrogen peroxide
(H2O2) and then to H2O by catalase, glutathione peroxidase (GPx)
or peroxiredoxin (Prx). Besides H2O2, GPx and Prx can also reduce
lipid peroxides. Thioredoxin (Trx) and glutaredoxin (Grx), on the
other hand, are involved in maintenance of the redox status of
protein thiols [171]. In addition to inhibition of GCL gene expres-
sion and therefore GSH biosynthesis, TGF-β also suppresses the
expression/activity of other antioxidant enzymes including SOD,
catalase, and Grx in different types of cells/tissues [83,91,119,172–
174]. Extracellular superoxide dismutase (EC-SOD) is protective in
several models of interstitial lung disease, including pulmonary
ﬁbrosis, and its expression is altered in the lung of IPF patient,
although the underlying mechanism is unclear [175]. Cui et al.
reported that TGF-β1 suppressed EC-SOD in cultured ﬁbroblasts in
vitro and in mouse lung tissue in vivo; overexpression of EC-SOD
in mouse lung by adenovirus mediated gene transfer technique, on
the other hand, blocked latent TGF-β1 activation and diminished
subsequent ﬁbrotic responses, suggesting an important role ofEC-SOD in TGF-β-induced ﬁbrogenesis [176]. In summary, TGF-β
stimulates ROS production and suppresses antioxidant defense,
leading to redox imbalance or oxidative stress (Fig. 1).4. Redox regulation of TGF-β1 activity and expression
TGF-β is synthesized and secreted into the extracellular space
as a large latent complex containing mature dimeric TGF-β bound
to latency-associated protein (LAP) and latent TGF-β-binding
protein (LTBP) [50,177,178]. Release of TGF-β from LAP, a process
called latent TGF-β activation, is required for the binding of TGF-β
to its receptors. Multiple mechanisms have been proposed for the
activation of latent TGF-β, including conformation changes in-
duced by thrombospondin-1 [179,180], binding to integrins ανβ6
and ανβ8 [181,182], proteolytic cleavage of LAP by plasmin and
matrix metalloproteinase [183–186], and oxidative modiﬁcation of
LAP or activation of MMPs, which then cleave LAP to release active
TGF-β [89,187–192]. LAP is sensitive to oxidation and oxidized LAP
loses its TGF-β binding capacity, leading to TGF-β activation. Oxi-
dants have been shown to activate latent TGF-β directly through
oxidation of LAP and indirectly through activation of MMPs such
as MMP-2 and MMP-9, which in turn cleave LAP to release active
TGF-β [89,188,192,193]. In vivo redox regulation of TGF-β activity
was also demonstrated in a recent study [176]. Cui et al. reported
that administration of AdTGF-β1 suppressed the expression of
ECSOD, which was associated with an increase in oxidative stress
and TGF-β activation in rat lung tissue [176]. Concomitant ad-
ministration of ECSOD expressing adenovirus AdECSOD, on the
other hand, signiﬁcantly reduced oxidative stress level and the
amount of active TGF-β and attenuated AdTGF-β1-induced lung
ﬁbrosis [176]. The results strongly suggest that TGF-β activity and
expression is regulated by redox status in vivo. Interestingly, it has
been reported that redox-mediated activation was restricted to the
TGF-β1 isoform [193]. Using site-speciﬁc mutation, a methionine
residue at amino acid position 253 unique to LAP-TGFβ1 was
identiﬁed to be critical for ROS-mediated activation of latent TGF-
β1 [193].
Besides directly activating latent TGF-β, numerous studies have
shown that ROS/RNS also upregulate TGF-β gene expression in
various types of cells [194–200]. In cultured human alveolar epi-
thelial cells, xanthine/xanthine oxidase derived ROS increased
TGF-β1 production through a transcriptional mechanism whereas
S-nitroso-N-acetyl-penicilamine generated RNS induced TGF-β1
through translational mechanisms [201]. Exogenous H2O2 has
been shown to induce the mRNA and protein expression of both
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(HUVECs) [199]. ROS generated endogenously in mitochondria or
by NADPH oxidases have also been shown to induce TGF-β [196].
Shvedova et al. reported that mice deﬁcient with gp91phox, the
prototype of NADPH oxidases, had reduced levels of TGF-β, com-
pared to wild type mice, indicating that Nox-derived ROS are the
major source of ROS for the induction of TGF-β [196]. A recent
study further showed that mitochondria-originated ROS were re-
sponsible for TGF-β induction in an allergic asthma model induced
by ovalbumin as mitochondria-targeted antioxidant (mitoTEMPO)
signiﬁcantly reduced ovalbumin-induced mitochondrial ROS and
TGF-β expression [198]. The signaling pathway mediating TGF-β
induction by ROS remains to be determined. Using small molecule
inhibitor and siRNA technique, Lin et al. reported that ROS medi-
ated hepatitis C virus-induced TGF-β1 expression through acti-
vating p38/JNK/ERK and NF-kβ pathways in human hepatocellular
carcinoma cells [197]. In summary, although numerous studies
have demonstrated that ROS induce TGF-β gene expression the
signaling pathway regulating ROS induction of TGF-β1, however,
remains poorly understood. In summary, redox imbalance due to
increased ROS production and/or decreased antioxidant defense,
in turn, can activate latent TGF-β1 and also induce TGF-β1 ex-
pression (Fig. 2), forming a vicious cycle.Fig. 2. Redox imbalance increases TGF-β1 activity. Redox imbalance due to in-
creased ROS and/or decreased antioxidants, in turn, activates latent TGF-β1 and
induces TGF-β1 gene expression, leading to an increase in TGF-β1 activity.5. ROS mediate TGF-β-induced ﬁbrotic responses
TGF-β promotes ﬁbrosis through diverse mechanisms, includ-
ing activation of resident ﬁbroblasts, stimulation of apoptosis in
epithelial and endothelial cells, induction of epithelial– or en-
dothelial–mesenchymal transition, production of ECM matrix
proteins, and suppressing ECM degradation. ROS have been shown
to mediate many of TGF-β-induced proﬁbrotic effects. In this
section, we will mainly focus on the role of ROS in TGF-β-induced
ﬁbroblast activation/myoﬁbroblast differentiation, epithelial
apoptosis, epithelial–mesenchymal transition (EMT/EnMT), and
the expression of proﬁbrogenic mediator, plasminogen activator
inhibitor 1 (PAI-1) as elucidated in Fig. 3.
5.1. TGF-β, ROS, and ﬁbroblast activation/myoﬁbroblast
differentiation
Myoﬁbroblasts are the major producers of extracellular matrix
(ECM) and therefore are key players in ﬁbrogenesis. Fibroblast
activation/differentiation to myoﬁbroblasts is a key in the initia-
tion and progression of ﬁbrosis and TGF-β plays a pivotal role in
myoﬁbroblast differentiation. A large body of literature show that
ROS, generated in mitochondria or by NADPH oxidases, are es-
sential for TGF-β-mediated myoﬁbroblast differentiation under
different pathological conditions [85,86,92,96,111,112,117,202].
Hecker et al. reported that knockdown of Nox4 with Nox4siRNA
suppressed TGF-β1-induced production of H2O2 and expression of
α-SMA, collagen, and ﬁbronectin, the markers of myoﬁbroblasts, inhuman fetal lung as well as IPF lung mesenchymal cells (hFLMCs)
[111]. Most importantly, they showed that administration of di-
phenyleneiodonium (DPI), a Nox inhibitor, or Nox4 siRNA abro-
gated lung ﬁbrosis in two murine lung ﬁbrosis models. Their data
support the notion that Nox4 induction is required for myoﬁbro-
blast differentiation and the development of lung ﬁbrosis [111].
Increased Nox4 expression has also been shown to mediate TGF-β-
induced activation of ﬁbroblasts from kidney, nasal polyss, liver,
and heart [92,96,118,202–204], although Nox4 was found to
function upstream of Smad in cardiac ﬁbroblasts [96] but down-
stream of Smad in human lung mesenchymal cells and nasal polys
[92,111]. Mitochondria-derived ROS are also involved in TGF-β-
induced myoﬁbroblast differentiation [85]. Interestingly, it was
reported that mitochondria derived ROS mediated TGF-β-induced
myoﬁbroblast differentiation in human lung ﬁbroblasts through
inducing Nox4 as inhibition of mitochondrial ROS by mitochon-
drial targeted antioxidant suppressed TGF-β-induced Nox4 ex-
pression and myoﬁbroblast differentiation [85]. Nonetheless, al-
though it has been well documented that ROS mediate TGF-β-in-
duced myoﬁbroblast differentiation, the molecular mechanisms or
signaling pathways whereby ROS mediate the phenotype transi-
tion remain unclear.
Increased resistance of myoﬁbroblasts to apoptosis is evident in
IPF [117,205,206] and in experimental lung ﬁbrosis models
[117,207]. It is therefore believed that increased apoptosis re-
sistance underlies the sustained myoﬁbroblast activation observed
in ﬁbrotic tissues. The mechanism underlying increased resistance
of myoﬁbroblasts to apoptosis is unknown. Hecker et al. have re-
ported that aged mice have impaired resolution of ﬁbrosis upon
bleomycin challenge, which is associated with the acquisition of
senescent and apoptosis-resistant phenotype of ﬁbroblasts [117].
They further show that Nox4 expression is increased in IPF lung
myoﬁbroblasts whereas Nrf2-mediated antioxidant response de-
clined in lung ﬁbroblasts isolated from aged mice, associated with
senescence and apoptosis resistance phenotype [117]. Most im-
portantly, they show that knockdown of Nox4 with siRNA reverses
the aging-related senescence and apoptosis resistance phenotype
of ﬁbroblasts [117]. Their results suggest that redox imbalance
resulting from elevated expression of Nox4 and an impaired Nrf2
antioxidant response underlies the acquisition of senescence and
apoptosis resistance phenotypes in myoﬁbroblasts from old mouse
lung and IPF patient [117]. Nonetheless, although increasing evi-
dence indicates that redox imbalance renders myoﬁbroblasts re-
sistance to apoptosis, the underlying mechanisms mediating the
ROS effect is unknown.
5.2. TGF-β, ROS, and epithelial apoptosis
TGF-β affects diverse cellular processes including cell pro-
liferation, differentiation, senescence, and apoptosis, depending on
cell types. Epithelium apoptosis is juxtaposed with ﬁbrosis and is
believed to contribute importantly to ﬁbrogenesis induced by
different stimuli in different organs. Apoptosis of type II alveolar
epithelial cells is evident in ﬁbrotic lung diseases including IPF and
in experimental ﬁbrosis model [117,205,206,208–214]. Studies
have demonstrated that epithelial apoptosis precedes and is re-
quired for TGF-b-induced lung ﬁbrosis [20]. Lee et al. reported that
overexpression of TGF-β1 in the lung of the inducible TGF-β triple
transgenic mice led to a transient wave of epithelial apoptosis that
was followed by inﬂammation and lung ﬁbrosis [20]. Knockout of
the early growth response gene (Egr-1) or administration of a
caspase inhibitor (Z-VAD-fmk) signiﬁcantly reduced TGF-β-in-
duced epithelial apoptosis as well as lung ﬁbrosis [20]. Their stu-
dies suggest strongly that epithelial apoptosis precede and is re-
quired for TGF-β-induced lung ﬁbrosis. Studies from other labs
further show that TGF-β induces senescence [81–83,85,87] and
Fig. 3. ROS mediate many of TGF-β1's proﬁbrogenic effects. ROS mediate TGF-β1-induced myoﬁbroblast differentiation, epithelial apoptosis, epithelial–mesenchymal
transition (EMT), and the expression of proﬁbrogenic mediators including PAI-1, which suppresses ECM degradation. By inducing myoﬁbroblast differentiation and thereby
ECM production and by suppressing ECM degradation through inducing PAI-1, TGF-β1 promotes ECM accumulation, ﬁbrosis.
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production from mitochondria or NADPH oxidases attenuated
TGF-β-induced cell senescence or apoptosis, suggesting an im-
portant role of ROS in TGF-β mediated epithelial senescence or
apoptosis. In a previous study, we showed that intranasal in-
stillation of TGF-β expressing adenovirus (AdTGF-β223/225) sup-
pressed the expression of GCL and reduced lung GSH, which was
associated with increased lipid peroxidation and epithelial apop-
tosis as well as massive lung ﬁbrosis in mice [25]. These data
further support the notion that TGF-β induces redox imbalance
in vivo, which underlies TGF-β-induced epithelial apoptosis and
lung ﬁbrosis.
5.3. ROS mediate TGF-induced epithelial–mesenchymal transition
Epithelial–mesenchymal transition (EMT/EnMT), a process
characterized by the loss of epithelial characteristics and the ac-
quisition of mesenchymal phenotype, is important in normal
embryonic development and is also co-opted in the pathogenesis
of diseases including cancer and ﬁbrosis. EMT is believed to be an
important source of myoﬁbroblasts during development of ﬁbrosis
in different organs [215–226]. TGF-β is the most potent inducer of
EMT and can induce EMT in epithelial cells from different organs
in vitro and in vivo [84,90,101,218,219,227–230]. Signaling path-
ways including Smad, MAPK, and PI3K pathways are involved in
the induction of EMT by TGF-β [231,232]. Importantly, ROS gen-
erated from different sources, including mitochondria and NOXs,
have been shown to mediate TGF-β-induced EMT in the settings of
cancer and ﬁbrosis [84,90,101,229,233]. Hirage et al. reported that
TGF-β induces Nox4 whereas Nox4 inhibitor DPI or siRNA blocked
TGF-β-induced EMT in pancreatic cancer cells [233]. They further
show that protein tyrosine phosphatase 1B (PTP1B) serves as a
redox sensor in TGF-β-induced Nox4/ROS-mediated EMT in thesetumor cells [233]. Nox4 has also been shown to mediate TGF-β-
induced EMT in human breast epithelial cells [101]. Kim and Cho
showed, on the other hand, that TGF-β induced Nox2, which was
responsible for the increase in ROS and the induction of epithelial–
mesenchymal transition in Hela cells [90]. They further identiﬁed a
new EMT regulator YB-1 as a downstream target in ROS-induced
EMT [90]. Mitochondria derived ROS have also been shown to
mediate TGF-β-induced EMT in mouse mammary epithelial cells
through a mitochondrial thioredoxin sensitive mechanism [84].
Evidence linking ROS to TGF-β-induced EMT in the context of ﬁ-
brosis is also bounty [228,234–237]. Rhyu et al. showed that TGF-β
increased ROS production and induced EMT in renal tubular epi-
thelial cells whereas inhibitors of NOX (DPI and apocynin), mi-
tochondria, and ERK MAPK blocked TGF-β-induced ROS produc-
tion and/or EMT. Their data suggest that ROS play an important
role in TGF-β1-induced EMT primarily through activation of MAPK
in proximal tubular epithelial cells [228]. Felton et al. reported that
TGF-β1 decreases intracellular GSH, increases ROS production, and
induces EMT in rat alveolar type II cells (RLE-6TN and primary);
N-acetylcysteine (NAC), GSH monoethyl ester reversed these ef-
fects induced by TGF-β1 [234]. They concluded that NAC prevents
TGF-β-induced EMT in vitro at least in part through replenishment
of intracellular GSH stores and suppression of TGF-β-induced in-
tracellular ROS generation [234]. Nox4 derived ROS have also been
shown to mediate TGF-β-induced EMT in renal tubular epithelial
cells [236,237]. Most interestingly, Lee et al. showed that metfor-
min, an AMP-activated protein kinase (AMPK) activator that has
been used in clinics for the treatment of diabetes, and 5-amino-
midazole-4-carboxamide-1β riboside (AICAR), another AMPK ac-
tivator suppressed TGF-β-induced EMT through inhibition of ROS
production, suggesting the potential therapeutic value of metfor-
min for ﬁbrosis by inhibition of ROS-mediated pathogenesis [236].
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hibitor 1 gene expression
ROS have been shown to mediate the induction of many matrix
structural proteins and pro-ﬁbrotic mediators by TGF-β1. In this sec-
tion, we will focus on one of these proteins, PAI-1. PAI-1 is a primary
inhibitor of urokinase-type and tissue-type plasminogen activators
(uPA and tPA, respectively). The primary function of PAI-1 is inhibition
of ﬁbrinolysis (hemostasis) through inhibition of tPA and uPA and
thereby activation of the zymogen plasminogen. Besides breaking
down ﬁbrin, plasmin is also involved in the degradation of extra-
cellular matrix (ECM) proteins directly or indirectly through activation
of matrix metalloproteinases (MMPs). Therefore, PAI-1 is believed to
play a role in the development of ﬁbrosis through inhibition of plas-
minogen activation and thus ECM degradation. PAI-1 expression is
increased in many ﬁbrotic diseases including IPF [238–243] and in
experimental ﬁbrosis models [244,245]. Knockout of the PAI-1 gene or
administration of PAI-1 siRNA attenuates, whereas overexpression of
PAI-1 protein enhances, ﬁbrotic responses induced by different stimuli
[26,53,54,168,207,242,246–248]. In a previous study, we showed that
inhibition of PAI-1 with a small molecule PAI-1 inhibitor attenuated
TGF-β1-induced lung ﬁbrosis in mice and the ﬁbrotic responses in
cultured lung ﬁbroblasts [26]. In a recent study, we further showed
that PAI-1 expression is increased with age in mouse lung tissue and
lung ﬁbroblasts, which was associated with increased apoptosis re-
sistance of lung ﬁbroblasts and increased sensitivity of old mice to
bleomycin-induced lung ﬁbrosis [207]. Inhibition of PAI-1 activity with
a small molecule PAI-1 inhibitor or knockdown of PAI-1 protein with
PAI-1 siRNA restored the sensitivity of lung ﬁbroblasts from old mice
to apoptosis [207]. Together, the data suggest that PAI-1 plays a critical
role in the development of lung ﬁbrosis, although the underlying
mechanism is under debating.
Many cytokines and chemokines as well as growth factors in-
duce PAI-1 and TGF-β is considered to be the most potent inducer.
TGF-β induces PAI-1 gene expression in various types of cells in
vitro and in vivo and an elevated PAI-1 level is also associated with
increased TGF-β expression and ECM deposition in diverse pa-
thological conditions, indicating a critical role of PAI-1 in TGF-β
ﬁbrogenesis [26,53,54,100,249–254]. Both Smad dependent and
independent pathways are involved in TGF-β induction of PAI-1
[255–257]. Ιmportantly, ROS have been shown to function as sig-
naling molecules mediating TGF-β-induced PAI-1 expression in
many of cell types [53,54,100,254,257–259]. GSH is the most
abundant intracellular free thiol and an important antioxidant.
Depletion of intracellular GSH leads to increased basal as well as
TGF-β1 or H2O2-induced PAI-1 expression whereas treatment with
N-acetylcysteine (NAC), a GSH precursor, suppresses TGF-β-in-
duced PAI-1 expression in kidney mesangial cells [258]. Our pre-
vious studies have also shown that treatment with exogenous GSH
or GSH ester suppresses TGF-β1-induced PAI-1 promoter activity,
PAI-1 mRNA and protein expression in murine embryo ﬁbroblasts
(NIH3T3 cells) through inhibition of JNK and p38, but not Smad,
pathways [53,54]. GSH treatment also reduces ROS level and re-
stores tPA activity as well as collagen degradation capacity in TGF-
β treated NIH3T3 cells [54]. Tubulointerstitial ﬁbrosis is a major
feature of several chronic renal diseases and TGF-β is the key in-
ducer of tubulointerstitial ﬁbrosis. A critical role of PAI-1 in the
development of kidney ﬁbrosis has been well demonstrated by
using mutant non-inhibitory PAI-1 protein [260–262]. Im-
portantly, studies have shown that ROS are essential for TGF-β-
mediated induction of PAI-1 in renal tubular epithelial cells or
mesangial cells through activation of ERK and p38 MAPK pathways
[258,263].
Although it has been well documented that ROS mediate TGF-
β-induced PAI-1 expression through activation of MAPK pathways,
the redox sensitive target(s) remain(s) unclear. Samarakoon et al.reported that TGF-β induces PAI-1 in vascular smooth muscle cells
(VSMCs) through two distinct pathways [264]. One of the path-
ways involves phosphorylation of epithelial growth factor receptor
(EGFR) on Y845, a Src kinase target residue, which leads to acti-
vation of ERK1/2 and then induction PAI-1 [264]. Another pathway
is through activation of RhoA-ROCK, which in turn phosphorylates
Smad2 and thus induces PAI-1 [264]. MAPKs are activated by
phosphorylation of threonine and tyrosine residues by MAPK ki-
nases, which, in turn, are phosphorylated and activated by MAPK
kinase kinases. Activated MAPKs, on the other hand, can be in-
activated by serine/threonine speciﬁc MAPK phosphatase (SS-
MKPs), tyrosine-speciﬁc MAPK phosphatases (TS-MKPs), or dual-
speciﬁc MAPK phosphatases (DS-MKPs). Many of MAPK phos-
phatases (MKPs), especially DS-MKPs, contain a redox sensitive
cysteine motif in their active sites and are sensitive to oxidative
inactivation by ROS/RNS. Our previous study showed that TGF-β1
increased the expression and activity of Nox4 in the nucleus of
mouse and human ﬁbroblasts, which was associated with in-
creased nuclear ROS production [100]. Most interestingly, we
showed that increased nuclear ROS led to thiol modiﬁcations and
inhibition of a nuclear DS-MKP, MKP-1 [100]. Knockdown of MKP-
1 expression with MKP-1 siRNA enhanced TGF-β1-induced JNK/
p38 phosphorylation and PAI-1 expression whereas knockdown of
Nox4 expression reduced TGF-β1-stimulated nuclear ROS pro-
duction, p38 phosphorylation, and PAI-1 expression. These data
reveal a novel mechanism whereby ROS modulate TGF-β signaling
and PAI-1 expression [100].6. In summary
TGF-β, the most potent proﬁbrogenic cytokine, increases ROS
production and suppresses antioxidant system. ROS in turn acti-
vate/induce TGF-β and mediate many of TGF-β's proﬁbrogenic
effects, including ﬁbroblast activation, epithelial/endothelial
apoptosis, EMT, and synthesis of proﬁbrogenic mediator such as
PAI-1. Therapeutic targeting of TGF-β-mediated ROS production
may provide beneﬁcial effect for the treatment of ﬁbrotic diseases.Acknowledgments
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